Squarepoint
ALXO icon

Squarepoint’s ALX Oncology ALXO Stock Holding History

Squarepoint’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-58,307
Closed -$24.2K – 4328
2025
Q2 		$24.2K Buy
+58,307
New +$29.4K ﹤0.01% 4378
2024
Q4 		– Sell
-137,983
Closed -$251K – 4991
2024
Q3 		$251K Buy
+137,983
New +$513K ﹤0.01% 3561
2024
Q2 		– Sell
-106,356
Closed -$1.19M – 4013
2024
Q1 		$1.19M Buy
+106,356
New +$1.49M ﹤0.01% 2471
2023
Q2 		– Sell
-63,231
Closed -$286K – 3527
2023
Q1 		$286K Buy
+63,231
New +$479K ﹤0.01% 2601
2022
Q4 		– Sell
-13,615
Closed -$130K – 3145
2022
Q3 		$130K Buy
+13,615
New +$159K ﹤0.01% 2763
2022
Q2 		– Sell
-13,189
Closed -$223K – 2847
2022
Q1 		$223K Sell
13,189
-34,016
-72% -$581K ﹤0.01% 2429
2021
Q4 		$1.01M Buy
+47,205
New +$2.04M ﹤0.01% 1680

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Squarepoint's ALXO Position: Q3 2025 in Review

Squarepoint sold out of ALX Oncology (ALXO) in Q3 2025, closing a stake of 58,307 shares — an estimated $24.2K sold.

Squarepoint first reported a position in ALXO in Q4 2021 and held it in 7 quarters. The position peaked at $1.19M in Q1 2024. 61 funds tracked by Wall St. Rank hold ALXO as of Q3 2025.

  • Squarepoint reported no remaining ALX Oncology position as of Q3 2025 after selling out during the quarter.
  • Squarepoint sold 58,307 ALX Oncology shares in Q3 2025, an estimated $24.2K.
  • Squarepoint first reported a position in ALX Oncology in Q4 2021 and held it in 7 quarters.
  • Squarepoint's ALX Oncology position peaked at $1.19M in Q1 2024.
  • 61 funds tracked by Wall St. Rank held ALX Oncology as of Q3 2025.

Based on Squarepoint's 13F filing for Q3 2025, filed 14 Nov 2025.